S C R U B B I N G U P implement in traditional healthcare settings , but in reality , it requires significant change management and integration with existing systems ,” van Lerberghe commented .
HealthTech startups particularly , can easily feel lost in the investments and regulation space and can feel that scaling their business or concept can feel out of reach . Buller advises that the process of scaling up depends on adaptability and knowledge of the process .
“ Understand the journey of scaling up , including regulatory and market differences across regions . Ensure you have the right team , investors , and advisors to support this journey . Focus on building a strong foundation with a clear regulatory strategy and a pathway to market . Be prepared to iterate and adapt based on feedback from stakeholders and regulatory bodies ,” said Buller .
There is no one-size-fits-all approach believes van Lerberghe . “ Partnering with the right people can be crucial for faster and more effective growth . Identifying who will pay for your solutions early on is also vital for sustaining and scaling your business . Make sure you have a thorough understanding of the healthcare ecosystem and the various stakeholders involved . Building strong relationships with key opinion leaders and healthcare providers can also facilitate market entry and adoption ,” added van Lerberghe .
The importance and goals of integrating these solutions into healthcare systems or within users ’ homes revolve around relieving the stresses on the public sector and improving public health . These technologies have evolved into a diverse range , from VR headset therapy to mobile ovulation tracking , many of which have become day-to-day assets to many patients and practitioners . Many of these solutions originated as startups that depended on investment and scaling to reach the market . Without this support , they might not exist today .
Buller reflects on the technologies , as someone working in the investment space , that he is most excited about . “ AI , especially in diagnostics and imaging , is significant . However , the key is the quality and access to data , which underpins the effectiveness of AI models . We invest in technologies that demonstrate real value and practical applications rather than just being trendy . For example , AI that can assist in early diagnosis and improve patient outcomes has immense potential . We are also excited about telemedicine platforms that expand access to care , particularly in underserved areas .”
With a different take , van Lerberghe is most excited about technologies that are more ‘ mundane ’. “ Technologies like exoskeletons for mobility impairments and advanced imaging for early detection of diseases are exciting . We also value seemingly mundane technologies that streamline essential processes , such as quality assurance in clinical trials . Digital therapeutics and personalised medicine are other areas with significant potential to transform healthcare delivery and outcomes . We look for technologies that can demonstrate both clinical efficacy and costeffectiveness ,” van Lerberghe concluded . �
www . intelligenthealth . tech 69